Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing ...

The early-stage trial results signal promise for ISB 2001, a first-in-class trispecific antibody being developed for patients ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Ola Landgren, MD, PhD, shares ADVANCE trial results, which show that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (DKRd) improves outcomes in newly diagnosed multiple myeloma.

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

In the dose-escalation stage of the trial, 35 patients were treated, most of whom had received a median of six prior ...

Renal failure in multiple myeloma typically occurs when the kidneys fail to filter waste products from the blood, leading to ...